Merck, 10033001-1VL, BRIN-BG5

Biochem/physiol Actions
A rat pancreatic Beta cell: RINm5F hybrid cell line. Insulin-secreting cell line
BRIN-BG5 is a hybrid cell line formed by the electrofusion of a primary culture of NEDH rat pancreatic islets with RINm5F (a cell line derived from a NEDH rat insuliinoma). BRIN-BG5 has been shown to be tumourigenic when transplanted into a SCID mouse host. BRIN-BG5 has been mycoplasma eradicated at ECACC and the stocks available for supply have undergone a further 10 passages without detection of mycoplasma.
Preparation Note
RPMI 1640 (R0883) + 2 mM L-Glutamine (G7513) + FBS / FCS (F2442)
Split sub-confluent cultures (70-80%) 1:8 to 1:10, i.e. seeding at 2-4 x 10⁴ cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37 °C. Population doubling approximately28hrs. At confluence 105 cells/cm² can be expected.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). Use of this product by commercial organizations may require a license agreement. Commercial customers will be contacted by [email protected] to provide further information after the order request is submitted. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to [email protected].
Disclaimer
This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.